|1.||Lobie, Peter E: 13 articles (09/2015 - 07/2002)|
|2.||Herndon, David N: 9 articles (03/2011 - 02/2002)|
|3.||Zhu, Tao: 7 articles (09/2015 - 05/2005)|
|4.||Perry, Jo K: 6 articles (05/2015 - 08/2008)|
|5.||Warady, Bradley A: 5 articles (10/2014 - 08/2007)|
|6.||Nishihara, Masugi: 5 articles (07/2014 - 12/2002)|
|7.||Jeschke, Marc G: 5 articles (03/2011 - 10/2004)|
|8.||Yamanouchi, Keitaro: 4 articles (07/2014 - 09/2006)|
|9.||Kotler, Donald P: 4 articles (01/2013 - 08/2002)|
|10.||Brown, Paul: 4 articles (05/2012 - 07/2003)|
|1.||Chronic Kidney Failure (Chronic Renal Failure)
07/01/1991 - "Treatment of nine boys, aged 2.8-16.3 years, with growth retardation consequent to chronic renal failure (CRF), with recombinant human growth hormone (rhGH) for 12-36 months demonstrated a significant improvement in growth velocity at each 12-month interval compared with that achieved the year prior to treatment. "
03/01/1994 - "Metabolic clearance of recombinant human growth hormone in health and chronic renal failure."
12/01/1993 - "Administration of recombinant human growth hormone (rhGH) ameliorates this problem but may adversely affect the kidney and hasten the progression to end-stage renal disease. "
12/01/2009 - "To develop a population pharmacokinetic (PK) model of recombinant human growth hormone (rhGH) treatment in patients with end-stage renal disease (ESRD) and healthy volunteers (HVs), to support future study design. "
06/01/2001 - "Dual energy X-ray absorptiometry of the whole body and the lumbar spine was performed to study bone mineralisation before and after 1 year of recombinant human growth hormone (rhGH) treatment in ten children with chronic renal failure. "
07/01/2004 - "The hypercatabolism after massive pediatric burns has been effectively treated with recombinant human growth hormone, an anabolic agent that stimulates protein synthesis and abrogates growth arrest. "
12/01/1991 - "The treatment of burn patients with recombinantly derived human growth hormone (rHGH) appears effective in counteracting protein catabolism. "
06/01/1992 - "Previous studies have shown that burn patients receiving recombinant human growth hormone (rhGH) therapy have an increase in the rate of skin donor site healing and a shorter hospital stay. "
01/01/2014 - "Recombinant human growth hormone (rhGH) increases protein synthesis, therefore it is used in burns with a total body surface area (TBSA) greater than 40%, where there is frequently an increase in protein breakdown and a decrease in protein synthesis. "
01/01/2014 - "Recombinant human growth hormone for treating burns and donor sites."
|3.||Turner Syndrome (Turner's Syndrome)
06/01/1996 - "The quality of life of Turner's syndrome can be much improved by early treatment with recombinant human growth hormone which significantly increases the patient's final height, and appropriate oestrogenic therapy at pubertal and adult ages. "
01/01/1993 - "Recombinant human growth hormone (GH) is effective in promoting growth velocity in subjects with Turner syndrome. "
01/01/1993 - "Safety and efficacy of human growth hormone treatment in girls with Turner syndrome."
07/01/2014 - "To study the effect of recombinant human growth hormone (rhGH) therapy on carbohydrate, lipid and protein metabolisms of Turner syndrome (TS). "
11/01/2012 - "This study analyzes the body anthropometric measurements in females with Turner syndrome (TS) not treated with recombinant human growth hormone. "
|4.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
05/01/2015 - "[Improvement in cardiac morphology and function in young rats with dilated cardiomyopathy by recombinant human growth hormone]."
03/28/1996 - "Recombinant human growth hormone administered for three months to patients with idiopathic dilated cardiomyopathy increased myocardial mass and reduced the size of the left ventricular chamber, resulting in improvement in hemodynamics, myocardial energy metabolism, and clinical status."
01/14/2000 - "This study was designed to evaluate the effects of treatment with recombinant human growth hormone (GH) on NO production and NO-dependent vascular effects in patients with dilated cardiomyopathy. "
10/01/1999 - "More recent studies have demonstrated beneficial effects in patients with CHF due to both ischaemic and idiopathic dilated cardiomyopathy, with improvements in haemodynamics when somatropin was added both as a maintenance therapy and as a short term infusion. "
05/01/2015 - "To investigate the effects of recombinant human growth hormone (rhGH) on the morphology and function of the left cardiac ventricle in young rats with dilated cardiomyopathy (DCM), and to evaluate the efficacy and safety of rhGH in the treatment of DCM. "
01/01/2003 - "Recently, somatropin administration was shown to induce improvement in hemodynamics and clinical status in some patients with heart failure. "
01/01/2008 - "To examine the efficacy and safety of recombinant human growth hormone (rhGH) therapy in congestive heart failure (CHF) by conducting a meta-analysis of clinical studies. "
02/01/2003 - "Experimental and clinical studies have shown that the administration of recombinant human growth hormone can improve deteriorated left ventricular function and hemodynamics in patients with heart failure. "
11/01/1998 - "This is the first double-blind and placebo-controlled study of the administration, over 3 months, of recombinant human growth hormone in patients with congestive heart failure of different aetiologies. "
05/01/2014 - "Eighty seven patients with chronic heart failure(> or = 60 years old) were randomly divided into 2 groups: the CHF control group (n = 46) who received regular therapy and the CHF experimental group (n = 41) who received regular therapy and recombinant human growth hormone. "
|1.||Growth Hormone (Somatotropin)
|2.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|3.||Human Growth Hormone (Saizen)
|9.||Insulin-Like Growth Factor I (IGF-1)
|10.||Epidermal Growth Factor (EGF)
|4.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)